piracetam has been researched along with Parkinson Disease in 9 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levodopa-treated PD participants with LID (n = 38) received LEV 500 mg/day, were assessed, titrated to 1,000 mg/day and reassessed, before and after crossover." | 2.76 | Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease. ( Konitsiotis, S; Peterson, D; Stathis, P; Tagaris, G, 2011) |
| "Levetiracetam was well tolerated at doses up to 2000 mg per day, but we did not detect any antidyskinetic properties." | 2.76 | A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease. ( Alty, JE; Goy, AG; Kempster, PA; Raghav, S; Reutens, DC; Wong, KK, 2011) |
| "We studied 6 patients with myoclonus elicited by flash stimulation (1-15 Hz)." | 1.29 | The pathophysiology and pharmacology of photic cortical reflex myoclonus. ( Artieda, J; Obeso, JA, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, S | 1 |
| Schwankhaus, J | 1 |
| Stathis, P | 1 |
| Konitsiotis, S | 1 |
| Tagaris, G | 1 |
| Peterson, D | 1 |
| Wong, KK | 1 |
| Alty, JE | 1 |
| Goy, AG | 1 |
| Raghav, S | 1 |
| Reutens, DC | 1 |
| Kempster, PA | 1 |
| Tousi, B | 1 |
| Subramanian, T | 1 |
| Zesiewicz, TA | 1 |
| Sullivan, KL | 1 |
| Maldonado, JL | 1 |
| Tatum, WO | 1 |
| Hauser, RA | 1 |
| Kurako, IuL | 1 |
| Volianskiĭ, VE | 1 |
| Finke, J | 1 |
| Artieda, J | 1 |
| Obeso, JA | 1 |
| Oepen, G | 1 |
| Eisele, K | 1 |
| Thoden, U | 1 |
| Birg, W | 1 |
1 review available for piracetam and Parkinson Disease
| Article | Year |
|---|---|
[New directions in contemporary pharmacotherapy of parkinsonism (review)].
Topics: Adrenergic beta-Antagonists; Anti-Anxiety Agents; Antiparkinson Agents; Apomorphine; Aromatic Amino | 1984 |
2 trials available for piracetam and Parkinson Disease
| Article | Year |
|---|---|
Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyski | 2011 |
A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease.
Topics: Anticonvulsants; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Ind | 2011 |
6 other studies available for piracetam and Parkinson Disease
| Article | Year |
|---|---|
Olfactory disturbance in Parkinson disease.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Biomarkers; Brain; | 2009 |
The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levetiracetam | 2005 |
Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levetiracetam | 2005 |
[Antiparkinson medication: increasing effectiveness with piracetam].
Topics: Aged; Antiparkinson Agents; Drug Synergism; Female; Humans; Male; Middle Aged; Parkinson Disease; Pi | 1980 |
The pathophysiology and pharmacology of photic cortical reflex myoclonus.
Topics: 5-Hydroxytryptophan; Aged; Aged, 80 and over; Ataxia; Cerebral Cortex; Dopamine Agents; Electroencep | 1993 |
Piracetam improves visuomotor and cognitive deficits in early Parkinsonism--a pilot study.
Topics: Aged; Cognition Disorders; Female; Humans; Male; Middle Aged; Parkinson Disease; Piracetam; Psychomo | 1985 |